Purple Book product · Reference 351(a)
Norditropin
somatropin
Mar 01, 2010
Approved
Reference 351(a)
License type
Rx
Marketing
None
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Approval
Approval date of this BLA submission.
Mar 01, 2010
16 yr 7 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
May 31, 2014
12 yr 4 mo ago
Today
Pharmaceutical detail
Strength
15MG/1.5ML
Dosage form
Injection
Route
Subcutaneous
Presentation
Autoinjector
Center
CDER
License number
1261
Product number
010
Submission type
Supplement
Supplement number
27
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.
10 additional BLA records for this product (other strengths or presentations) are in the same reference family.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
Change history
- v2Jul 02, 2026
Frequently asked questions
Does Norditropin have approved biosimilars?
No 351(k) biosimilars or interchangeable biosimilars referencing Norditropin are listed in the FDA Purple Book yet.
What is Norditropin's BLA number?
Norditropin is licensed under BLA 021148, held by Novo Nordisk Inc..
When was Norditropin approved by the FDA?
Norditropin was approved by the FDA on Mar 01, 2010.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
